HeimBMRN • NASDAQ
add
Biomarin Pharmaceutical Inc
Við síðustu lokun
68,38 $
Dagbil
66,01 $ - 67,94 $
Árabil
61,15 $ - 96,65 $
Markaðsvirði
12,84 ma. USD
Meðalmagn
1,39 m.
V/H-hlutf.
40,53
A/V-hlutfall
-
Aðalkauphöll
NASDAQ
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (USD) | sep. 2024info | Breyting á/á |
|---|---|---|
Tekjur | 745,74 m. | 28,28% |
Rekstrarkostnaður | 443,39 m. | 4,88% |
Nettótekjur | 106,08 m. | 162,72% |
Hagnaðarhlutfall | 14,22 | 104,60% |
Hagnaður á hvern hlut | 0,91 | 97,83% |
EBITDA | 132,90 m. | 136,43% |
Virkt skatthlutfall | 21,10% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (USD) | sep. 2024info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 930,44 m. | -17,36% |
Heildareignir | 6,85 ma. | 1,38% |
Heildarskuldir | 1,44 ma. | -22,75% |
Eigið fé alls | 5,41 ma. | — |
Útistandandi hlutabréf | 190,58 m. | — |
Eiginfjárgengi | 2,41 | — |
Arðsemi eigna | 4,09% | — |
Ávöxtun eigin fjár | 4,59% | — |
Peningaflæði
Breyting á handbæru fé
| (USD) | sep. 2024info | Breyting á/á |
|---|---|---|
Nettótekjur | 106,08 m. | 162,72% |
Handbært fé frá rekstri | 221,48 m. | 63,28% |
Reiðufé frá fjárfestingum | -16,16 m. | 64,72% |
Reiðufé frá fjármögnun | -499,12 m. | -63.240,74% |
Breyting á handbæru fé | -296,70 m. | -425,93% |
Frjálst peningaflæði | 165,57 m. | 86,81% |
Um
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research is in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria.
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
Framkvæmdastjóri
Stofnsett
mar. 1997
Höfuðstöðvar
Vefsvæði
Starfsfólk
3.401
